tiprankstipranks
CSL (CMXHF)
OTHER OTC:CMXHF
US Market
CMXHF
CSL
RESEARCH TOOLSreports

CSL (CMXHF) Stock Forecast & Price Target

85 Followers
See the Price Targets and Ratings of:

CMXHF Analyst Ratings

Moderate Buy
11Ratings
Moderate Buy
3 Buy
8 Hold
0 Sell
Based on 11 analysts giving stock ratings to
CSL
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CMXHF Stock 12 Month Forecast

Average Price Target

$99.99
▲(2.63% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for CSL in the last 3 months. The average price target is $99.99 with a high forecast of $166.00 and a low forecast of $72.01. The average price target represents a 2.63% change from the last price of $97.43.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"71":"$71","97":"$97","123":"$123","149":"$149","175":"$175"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":165.999999468966,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$166.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":99.99069904263327,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$99.99</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":72.00999999999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$72.01</span>\n  </div></div>","useHTML":true}}],"tickPositions":[71,97,123,149,175],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,89.96,95.80923072838199,101.658461456764,107.507692185146,113.356922913528,119.20615364190999,125.05538437029199,130.90461509867401,136.753845827056,142.603076555438,148.45230728382,154.301538012202,160.150768740584,{"y":165.999999468966,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,89.96,90.7315922340487,91.50318446809742,92.27477670214613,93.04636893619485,93.81796117024356,94.58955340429227,95.36114563834099,96.1327378723897,96.90433010643841,97.67592234048713,98.44751457453584,99.21910680858456,{"y":99.99069904263327,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,89.96,88.57923076923076,87.19846153846153,85.8176923076923,84.43692307692307,83.05615384615383,81.67538461538462,80.29461538461538,78.91384615384615,77.53307692307692,76.15230769230769,74.77153846153846,73.39076923076922,{"y":72.00999999999999,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":162.883,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":158.151,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":147.265,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.117,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.918,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.324,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.868,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.079,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.96,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.712,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.823,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.49,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.96,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$166.00Average Price Target$99.99Lowest Price Target$72.01
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on CMXHF
David Stanton
Jefferies
Jefferies
$140.42→$77.77
Hold
-20.18%
Downside
Downgraded
05/29/26
Analysts Are Neutral on These Healthcare Stocks: CSL (CMXHF), ONO Pharmaceutical Co (OPHLF)
Morgan Stanley Analyst forecast on CMXHF
David Bailey
Morgan Stanley
Morgan Stanley
$166
Buy
70.38%
Upside
Reiterated
05/24/26
CSL (CMXHF) Receives a Buy from Morgan Stanley
Citi Analyst forecast on CMXHF
Laura Sutcliffe
Citi
Citi
$79.21
Hold
-18.70%
Downside
Reiterated
05/14/26
Citi Sticks to Its Hold Rating for CSL (CMXHF)
Ord Minnett Analyst forecast on CMXHF
Unknown Analyst
Ord Minnett
Not Ranked
Ord Minnett
$133.94→$97.21
Hold
-0.22%
Downside
Reiterated
05/12/26
Ord Minnett Keeps Their Hold Rating on CSL (CMXHF)
Jarden Analyst forecast on CMXHF
Steven Wheen
Jarden
Jarden
$175.7→$137.54
Hold
41.17%
Upside
Downgraded
05/12/26
Jarden downgrades CSL (CMXHF) to a Hold
UBS Analyst forecast on CMXHF
David Low
UBS
UBS
$147.62→$126.02
Buy
29.34%
Upside
Reiterated
05/12/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: CSL (Other OTC: CMXHF) and Tandem Diabetes Care (NASDAQ: TNDM)
Canaccord Genuity Analyst forecast on CMXHF
Shane Storey
Canaccord Genuity
Canaccord Genuity
$129.62→$76.55
Hold
-21.43%
Downside
Downgraded
05/12/26
Canaccord Genuity downgrades CSL (CMXHF) to a Hold
Morgans Analyst forecast on CMXHF
Derek Jellinek
Morgans
Morgans
$173.79→$106.28
Buy
9.08%
Upside
Reiterated
05/12/26
CSL (CMXHF) Receives a Buy from Morgans
Macquarie Analyst forecast on CMXHF
Christine Trinh
Macquarie
Macquarie
$126.74→$79.93
Hold
-17.96%
Downside
Reiterated
05/11/26
Macquarie Sticks to Their Hold Rating for CSL (CMXHF)
RBC Capital Analyst forecast on CMXHF
Craig Wong-Pan
RBC Capital
RBC Capital
$81.37
Hold
-16.48%
Downside
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: CSL (Other OTC: CMXHF) and Apogee Therapeutics (NASDAQ: APGE)
Bell Potter Analyst forecast on CMXHF
Thomas Wakim
Bell Potter
Bell Potter
$111.62→$72.01
Hold
-26.09%
Downside
Reiterated
05/11/26
CSL (CMXHF) Receives a Hold from Bell Potter
Goldman Sachs Analyst forecast on CMXHF
Davinthra Thillainathan
Goldman Sachs
Goldman Sachs
$223.95→$152.73
Buy
56.76%
Upside
Reiterated
10/29/25
Goldman Sachs Reaffirms Their Buy Rating on CSL (CMXHF)
CLSA Analyst forecast on CMXHF
Andrew Paine
CLSA
CLSA
$226.83→$198.03
Buy
103.25%
Upside
Reiterated
10/13/25
CLSA Keeps Their Buy Rating on CSL (CMXHF)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on CMXHF
David Stanton
Jefferies
Jefferies
$140.42→$77.77
Hold
-20.18%
Downside
Downgraded
05/29/26
Analysts Are Neutral on These Healthcare Stocks: CSL (CMXHF), ONO Pharmaceutical Co (OPHLF)
Morgan Stanley Analyst forecast on CMXHF
David Bailey
Morgan Stanley
Morgan Stanley
$166
Buy
70.38%
Upside
Reiterated
05/24/26
CSL (CMXHF) Receives a Buy from Morgan Stanley
Citi Analyst forecast on CMXHF
Laura Sutcliffe
Citi
Citi
$79.21
Hold
-18.70%
Downside
Reiterated
05/14/26
Citi Sticks to Its Hold Rating for CSL (CMXHF)
Ord Minnett Analyst forecast on CMXHF
Unknown Analyst
Ord Minnett
Not Ranked
Ord Minnett
$133.94→$97.21
Hold
-0.22%
Downside
Reiterated
05/12/26
Ord Minnett Keeps Their Hold Rating on CSL (CMXHF)
Jarden Analyst forecast on CMXHF
Steven Wheen
Jarden
Jarden
$175.7→$137.54
Hold
41.17%
Upside
Downgraded
05/12/26
Jarden downgrades CSL (CMXHF) to a Hold
UBS Analyst forecast on CMXHF
David Low
UBS
UBS
$147.62→$126.02
Buy
29.34%
Upside
Reiterated
05/12/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: CSL (Other OTC: CMXHF) and Tandem Diabetes Care (NASDAQ: TNDM)
Canaccord Genuity Analyst forecast on CMXHF
Shane Storey
Canaccord Genuity
Canaccord Genuity
$129.62→$76.55
Hold
-21.43%
Downside
Downgraded
05/12/26
Canaccord Genuity downgrades CSL (CMXHF) to a Hold
Morgans Analyst forecast on CMXHF
Derek Jellinek
Morgans
Morgans
$173.79→$106.28
Buy
9.08%
Upside
Reiterated
05/12/26
CSL (CMXHF) Receives a Buy from Morgans
Macquarie Analyst forecast on CMXHF
Christine Trinh
Macquarie
Macquarie
$126.74→$79.93
Hold
-17.96%
Downside
Reiterated
05/11/26
Macquarie Sticks to Their Hold Rating for CSL (CMXHF)
RBC Capital Analyst forecast on CMXHF
Craig Wong-Pan
RBC Capital
RBC Capital
$81.37
Hold
-16.48%
Downside
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: CSL (Other OTC: CMXHF) and Apogee Therapeutics (NASDAQ: APGE)
Bell Potter Analyst forecast on CMXHF
Thomas Wakim
Bell Potter
Bell Potter
$111.62→$72.01
Hold
-26.09%
Downside
Reiterated
05/11/26
CSL (CMXHF) Receives a Hold from Bell Potter
Goldman Sachs Analyst forecast on CMXHF
Davinthra Thillainathan
Goldman Sachs
Goldman Sachs
$223.95→$152.73
Buy
56.76%
Upside
Reiterated
10/29/25
Goldman Sachs Reaffirms Their Buy Rating on CSL (CMXHF)
CLSA Analyst forecast on CMXHF
Andrew Paine
CLSA
CLSA
$226.83→$198.03
Buy
103.25%
Upside
Reiterated
10/13/25
CLSA Keeps Their Buy Rating on CSL (CMXHF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering CSL

3 Months
David BaileyMorgan Stanley
Success Rate
7/20 ratings generated profit
35%
Average Return
-5.38%
Copying David Bailey's trades and holding each position for 3 Months would result in 35.00% of your transactions generating a profit, with an average return of -5.38% per trade.
1 Year
Andrew PaineCLSA
Success Rate
8/23 ratings generated profit
35%
Average Return
-7.49%
Copying Andrew Paine's trades and holding each position for 1 Year would result in 34.78% of your transactions generating a profit, with an average return of -7.49% per trade.
2 Years
Andrew PaineCLSA
Success Rate
5/23 ratings generated profit
22%
Average Return
-17.56%
Copying Andrew Paine's trades and holding each position for 2 Years would result in 21.74% of your transactions generating a profit, with an average return of -17.56% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CMXHF Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
6
5
8
11
14
Buy
6
10
11
8
1
Hold
5
9
8
10
14
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
24
27
29
29
In the current month, CMXHF has received 15 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. CMXHF average Analyst price target in the past 3 months is 99.99.
Each month's total comprises the sum of three months' worth of ratings.

CMXHF Financial Forecast

CMXHF Earnings Forecast

Next quarter’s earnings estimate for CMXHF is $2.23 with a range of $1.74 to $2.36. The previous quarter’s EPS was $4.03. CMXHF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CMXHF has Performed in-line its overall industry.
Next quarter’s earnings estimate for CMXHF is $2.23 with a range of $1.74 to $2.36. The previous quarter’s EPS was $4.03. CMXHF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CMXHF has Performed in-line its overall industry.

CMXHF Sales Forecast

Next quarter’s sales forecast for CMXHF is $7.12B with a range of $6.78B to $7.40B. The previous quarter’s sales results were $9.00B. CMXHF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CMXHF has Performed in-line its overall industry.
Next quarter’s sales forecast for CMXHF is $7.12B with a range of $6.78B to $7.40B. The previous quarter’s sales results were $9.00B. CMXHF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CMXHF has Performed in-line its overall industry.

CMXHF Stock Forecast FAQ

What is CMXHF’s average 12-month price target, according to analysts?
Based on analyst ratings, CSL’s 12-month average price target is 99.99.
    What is CMXHF’s upside potential, based on the analysts’ average price target?
    CSL has 2.63% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CMXHF a Buy, Sell or Hold?
          CSL has a consensus rating of Moderate Buy which is based on 3 buy ratings, 8 hold ratings and 0 sell ratings.
            What is CSL’s price target?
            The average price target for CSL is 99.99. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $166.00 ,the lowest forecast is $72.01. The average price target represents 2.63% Increase from the current price of $97.43.
              What do analysts say about CSL?
              CSL’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of CMXHF?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.